The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kelly Paul Edward since 2015.
This trader's CIK number is 1658544.
At the time of last reporting, Kelly Paul Edward was the Chief Operating Officer of Relmada Therapeutics, Inc.. (stock ticker symbol RLMD).
Also see all insider trading activities at Relmada Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RLMD | 200,000 | $86,000 | 0 | $0 | 0 | $0 |
| 2024 | RLMD | 25,000 | $64,750 | 0 | $0 | 0 | $0 |
| 2022 | RLMD | 0 | $0 | 10,000 | $300,400 | 30,000 | $97,200 |
| 2021 | RLMD | 0 | $0 | 25,000 | $4,551,639 | 45,000 | $159,599 |
| 2020 | RLMD | 0 | $0 | 0 | $0 | 22,000 | $71,280 |
| 2019 | RLMD | 105,000 | $245,450 | 0 | $0 | 0 | $0 |
| 2018 | RLMD | 155,000 | $141,065 | 0 | $0 | 0 | $0 |
| 2015 | RLMD | 10,000 | $28,400 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-16 | RLMD | Buy | 200,000 | .43 | 86,000 |
| 2024-09-09 | RLMD | Buy | 25,000 | 2.59 | 64,750 |
| 2022-04-04 | RLMD | Option Ex | 10,000 | 3.24 | 32,400 |
| 2022-04-04 | RLMD | Sale | 10,000 | 30.04 | 300,400 |
| 2022-01-03 | RLMD | Option Ex | 20,000 | 3.24 | 64,800 |
| 2021-03-09 | RLMD | Option Ex | 5,000 | 3.24 | 16,200 |
| 2021-03-09 | RLMD | Sale | 5,000 | 35.87 | 179,355 |
| 2021-02-24 | RLMD | Sale | 5,000 | 34.63 | 173,145 |
| 2021-02-24 | RLMD | Option Ex | 5,000 | 3.24 | 16,200 |
| 2021-02-16 | RLMD | Option Ex | 5,000 | 6.00 | 30,000 |
| 2021-02-08 | RLMD | Option Ex | 3,569 | 3.24 | 11,563 |
| 2021-02-08 | RLMD | Sale | 1,500 | 35.04 | 52,560 |
| 2021-02-09 | RLMD | Sale | 2,069 | 35.28 | 73,004 |
| 2021-02-01 | RLMD | Option Ex | 17,346 | 3.24 | 56,201 |
| 2021-02-01 | RLMD | Sale | 31 | 35.00 | 1,085 |
| 2021-02-02 | RLMD | Sale | 2,315 | 35.04 | 81,117 |
| 2021-01-27 | RLMD | Option Ex | 5,000 | 3.24 | 16,200 |
| 2021-01-27 | RLMD | Sale | 5,000 | 32.66 | 163,299 |
| 2021-01-26 | RLMD | Sale | 685 | 35.16 | 24,084 |
| 2021-01-25 | RLMD | Sale | 1,300 | 35.27 | 45,851 |
| 2021-01-22 | RLMD | Sale | 2,100 | 1,789.59 | 3,758,139 |
| 2021-01-22 | RLMD | Option Ex | 4,085 | 3.24 | 13,235 |
| 2020-08-18 | RLMD | Option Ex | 22,000 | 3.24 | 71,280 |
| 2019-10-18 | RLMD | Buy | 5,000 | 19.09 | 95,450 |
| 2019-05-14 | RLMD | Buy | 100,000 | 1.50 | 150,000 |
| 2018-12-11 | RLMD | Buy | 5,000 | 1.21 | 6,065 |
| 2018-10-12 | RLMD | Buy | 150,000 | .90 | 135,000 |
| 2015-12-14 | RLMD | Buy | 10,000 | 2.84 | 28,400 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kelly Paul Edward (Chief Operating Officer of Relmada Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.